MC0704 is a STAT3 inhibitor with an IC50 value of 2.13 μM. MC0704 induces cell apoptosis and cell cycle arrest. MC0704 shows antitumor activity in mouse breast cancer models. MC0704 can be used for the research of metastatic triple-negative breast cancer (mTNBC)[1].
in vivo
MC0704 (10 mg/kg; i.p., 10 mg/kg, once daily for 12 days) inhibits cancer growth of mice with MDA-MB-231-DTR cells transplant[1].
Animal Model:
Female BALB/c-nu mice with MDA-MB-231-DTR cells transplant[1]
Dosage:
10 mg/kg
Administration:
Intraperitoneal injection; 10 mg/kg, once daily for 12 days
Result:
Significantly inhibited tumor growth without overt toxicity, and reversed the mesenchymal marker vimentin and epithelial marker E-cadherin expression changes.
References
[1] Byun WS, et al. Design, Synthesis, and Biological Activity of Marinacarboline Analogues as STAT3 Pathway Inhibitors for Docetaxel-Resistant Triple-Negative Breast Cancer. J Med Chem. 2023 Feb 23;66(4):3106-3133. DOI:10.1021/acs.jmedchem.2c01115
